JP2007511463A - 作用物質の組織特異的送達のための内皮の標的化 - Google Patents

作用物質の組織特異的送達のための内皮の標的化 Download PDF

Info

Publication number
JP2007511463A
JP2007511463A JP2006522051A JP2006522051A JP2007511463A JP 2007511463 A JP2007511463 A JP 2007511463A JP 2006522051 A JP2006522051 A JP 2006522051A JP 2006522051 A JP2006522051 A JP 2006522051A JP 2007511463 A JP2007511463 A JP 2007511463A
Authority
JP
Japan
Prior art keywords
caveolae
agent
component
luminal surface
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006522051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511463A5 (https=
Inventor
シュニッツァー，ジャン，イー．
Original Assignee
ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
シドニー キンメル キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド, シドニー キンメル キャンサー センター filed Critical ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
Publication of JP2007511463A publication Critical patent/JP2007511463A/ja
Publication of JP2007511463A5 publication Critical patent/JP2007511463A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006522051A 2003-07-31 2004-07-29 作用物質の組織特異的送達のための内皮の標的化 Pending JP2007511463A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/631,481 US20040115128A1 (en) 1995-09-08 2003-07-31 Targeting endothelium for tissue-specific delivery of agents
PCT/US2004/024448 WO2005012489A2 (en) 2003-07-31 2004-07-29 Targeting endothelium for tissue-specific delivery of agents

Publications (2)

Publication Number Publication Date
JP2007511463A true JP2007511463A (ja) 2007-05-10
JP2007511463A5 JP2007511463A5 (https=) 2007-09-13

Family

ID=34115771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522051A Pending JP2007511463A (ja) 2003-07-31 2004-07-29 作用物質の組織特異的送達のための内皮の標的化

Country Status (6)

Country Link
US (2) US20040115128A1 (https=)
EP (1) EP1664272A4 (https=)
JP (1) JP2007511463A (https=)
AU (1) AU2004261988B2 (https=)
CA (1) CA2537899A1 (https=)
WO (1) WO2005012489A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
EP1755686A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US7810718B2 (en) * 2005-05-12 2010-10-12 Cubic Corporation Variable thickness data card body
US20070106271A1 (en) 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US9474712B2 (en) * 2005-11-09 2016-10-25 Gearbox, Llc In situ reaction device
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8936590B2 (en) * 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8273075B2 (en) 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
US8992511B2 (en) 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20080140057A1 (en) 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
WO2015006501A2 (en) * 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US20030008819A1 (en) * 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602005A (en) * 1989-03-03 1997-02-11 The University Of Virginia Alumni Patents Foundation Primate intra-acrosomal sperm antigen for use in a contraceptive vaccine
US5281700A (en) * 1992-08-11 1994-01-25 The Regents Of The University Of California Method of recovering endothelial membrane from tissue and applications thereof
US5776770A (en) * 1995-09-08 1998-07-07 Beth Israel Deaconess Medical Center Isolation and uses of caveolae
EP0848614B1 (en) * 1995-09-08 2006-04-26 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US20030008819A1 (en) * 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents

Also Published As

Publication number Publication date
WO2005012489A2 (en) 2005-02-10
US20070160531A1 (en) 2007-07-12
EP1664272A2 (en) 2006-06-07
EP1664272A4 (en) 2011-05-25
AU2004261988B2 (en) 2007-10-04
AU2004261988A1 (en) 2005-02-10
CA2537899A1 (en) 2005-02-10
US20040115128A1 (en) 2004-06-17
WO2005012489A3 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
US20070160531A1 (en) Targeting endothelium for tissue-specific delivery of agents
JP2008189674A (ja) カベオレおよびｇｐｉアンカー蛋白質のマイクロドメインの単離
Wang et al. Interrogation of folic acid-functionalized nanomedicines: the regulatory roles of plasma proteins reexamined
Beldman et al. Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy
Huang et al. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice
Moghimi et al. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system–the concept of tissue specificity
Francia et al. Corona composition can affect the mechanisms cells use to internalize nanoparticles
Ho et al. Influence of protein corona and caveolae-mediated endocytosis on nanoparticle uptake and transcytosis
Ran et al. Increased exposure of anionic phospholipids on the surface of tumor blood vessels
Schnitzer Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo
Murate et al. Transbilayer distribution of lipids at nano scale
Yap et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases
Cieutat et al. Azurophilic granules of human neutrophilic leukocytes are deficient in lysosome-associated membrane proteins but retain the mannose 6-phosphate recognition marker
US5328840A (en) Method for preparing targeted carrier erythrocytes
Michaely et al. The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits
JPH11504329A (ja) 細胞死の抑制および細胞中への作用物の分配に有用な組成物および方法
Kullberg et al. Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells
Zamora et al. Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system
Sternberg et al. Surface-modified loaded human red blood cells for targeting and delivery of drugs
Brenner et al. The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series)
Almeda et al. Minimizing antibody surface density on liposomes while sustaining cytokine-activated EC targeting
US20030008819A1 (en) Targeting endothelium for tissue-specific delivery of agents
US5914127A (en) Isolation and uses of caveolae
Murciano et al. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries
Katzir et al. Role of the plasma membrane leaflets in drug uptake and multidrug resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110407